Skip to main content
SpringerLink
Log in

Die Bedeutung der Östrogene für gutartige und bösartige Brusterkrankungen

  • Conference paper
Östrogene in Diagnostik und Therapie

  • 30 Accesses

Zusammenfassung

Wachstum und Entwicklung der weiblichen Brustdrüse werden nomalerweise hauptsächlich durch die ovarielle Sekretion von Östrogenen und Progesteron bestimmt. Dabei sind Östrogene (vor allem Östradiol) die wichtigsten direkten Hormone für das Wachstum der 4 Gewebestrukturen der Brust (Fettgewebe, Bindegewebe, duktales und lobuläres System). Die Ausdifferenzierung der duktalen und lobulären Strukturen wird durch Gestagene (Progesteron) erreicht. Eine optimale duktal-lobuläre Morphologie setzt den ausgewogenen Synergismus von Östrogenen und Gestagenen voraus. Dabei spielen Bindungsproteine, aber auch die Reaktion des Gewebes (Rezeptorbildung undfunktion) eine Rolle. Die volle natürliche Ausreifung der Brust wird normalerweise durch die erste ausgetragene Schwangerschaft herbeigeführt.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 54.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 69.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Ayers JWT, Gidwani GP (1983) The “luteal breast”: Hormonal and Sonographie investigations of benign breast disease in patients with cyclic mastalgia. Fertil Steril 40:779–784

    PubMed  CAS  Google Scholar 

  2. Bässler R (1978) Pathologie der Brustdrüse. Springer, Berlin Heidelberg New York (Spezielle pathologische Anatomie Bd. 11)

    Google Scholar 

  3. Berta L, Frairia R, Brumma C, Mavello C, Mosetto C, Rovero E, Gaidano G (1983) Hormonal pattern and sex-hormone binding globulin in plasma of women with cystic breast disease. In: Angeli A, Bradlow HL, Dogliotti L (eds) Endocrinology of cystic breast disease. Raven Press, New York, pp 123–126

    Google Scholar 

  4. Brüning PF, Bonfrer JMG, Hart AAM (1985) Non protein bound estradiol, sex-hormone binding globulin, breast cancer and breast cancer risk. Br J Cancer 51:479–484

    Article  PubMed  Google Scholar 

  5. Bucher NLR, Geschickter CF (1941) Corpus luteum studies: 2. Pregnandiol and estrogen output in the urine of patients with chronic cystic mastitis. J Clin Endocrinol Metab 1:58–63

    Article  CAS  Google Scholar 

  6. Christensen SB (1987) Correlation between non-toxic goitre and benign mastopathia. Acta Med Scand 221:395–401

    Article  Google Scholar 

  7. Cole P, Ellwood JM, Kaplan SD (1978) Incidence rates and risk factors of benign breast neoplasm. Am J Epidemiol 108:112–116

    PubMed  CAS  Google Scholar 

  8. Cuzick J, Wang DY, Bulbrook RD (1986) The prevention of breast cancer. Lancet I:83–85

    Article  Google Scholar 

  9. Davis HH, Simons M, Davis JB (1964) Cystic disease of the breast. Relationship to cancer. Cancer 17:957–961

    Article  PubMed  CAS  Google Scholar 

  10. Drafta D, Schindler AE, Milcu STM, Keller E, Stroe E, Horodniceanu E, Balanescu I (1980) Plasma hormones in pre- and postmenopausal breast cancer patients. J Steroid Biochem 13:793–802

    Article  PubMed  CAS  Google Scholar 

  11. Dupont WD, Page DL (1985) Risk factors for breast cancer in women with proliferative breast disease. N Engl J Med 312:146–151

    Article  PubMed  CAS  Google Scholar 

  12. Enriori CL, Reforzo-Membrives J (1984) Peripheral aromatisation as a risk factor for breast and endometrial cancer in postmenopausal women: A Review. Gynecol Oncol 17:1–21

    Article  PubMed  CAS  Google Scholar 

  13. Gambrell RD (1984) Proposal to decrease the risk and to improve the prognosis of breast cancer. Am J Obstet Gynecol 150:119–132

    PubMed  Google Scholar 

  14. Greenblatt RB, Chadda JS, Teran AZ, Lewis A (1984) Fibrocystic breast disease: Pathophysiology, hormonology, treatment. Contemp Surg 24:49–60

    Google Scholar 

  15. Gregl A (1983) Bei der bunten Mischung der Mastopathie empfiehlt es sich, den Köcher der hormonalen Therapie möglichst auszuschöpfen. Gynäkologe 3:16–19

    Google Scholar 

  16. Harris JR, Hellmann S, Henderson IC, Kinne DW (1987) Breast diseases. Lippincott, Philadelphia

    Google Scholar 

  17. Hirayama T, Wynder EL (1962) A study of the epidemiology of cancer of the breast II. The influence of hysterectomy. Cancer 15:28–38

    Article  Google Scholar 

  18. Hoover R, Glass A, Finkle WD, Azevedo D, Milne K (1981) Conjugates estrogens and breast cancer risk in women. J Natl Cancer Inst 67:815 – 820

    PubMed  CAS  Google Scholar 

  19. Key TJA, Pike MC (1988) The role of estrogen and progestogens in the epidemiology and prevention of breast cancer. Eur J Cancer Clin Oncol 24:29–43

    Article  PubMed  CAS  Google Scholar 

  20. Kodlin D, Winger EE, Morgenstern NL, Chen V (1977) Chronic mastopathy and breast cancer. Cancer 39:2603–2607

    Article  PubMed  CAS  Google Scholar 

  21. Kumar S, Mansel RE, Hughes LE, Edwards CA, Scanlon MF (1985) Prediction of response to endocrine therapy in pronounced mastalgia using dynamic tests of prolactin release. Clin Endocrinol 23:699–704

    Article  CAS  Google Scholar 

  22. Kvale G, Hench I (1988) Menstrual factors and breast cancer risk. Cancer 62:1625–1631

    Article  PubMed  CAS  Google Scholar 

  23. MacMahon B, Feinelib M (1960) Breast cancer in relation to nursing and menopausal history. J Natl Cancer Inst 24:733–753

    PubMed  CAS  Google Scholar 

  24. MacMahon B, Trichopoulos D, Brown J, Andersen A, Cole P, De Waard F, Kouraniemi T, Polychronopoulou A, Ravnihar B, Stormly N, Westlund K (1982) Age at menarche, urine estrogens and breast cancer risk. Int J Cancer 30:427–431

    Article  PubMed  CAS  Google Scholar 

  25. Marx E, Schulz H, Maecker R (1969) Klinische Bewertung der Epithelproliferation gutartiger Mammatumoren und Mastopathien. Brun’s Beitr Klin Chir 217:220–231

    CAS  Google Scholar 

  26. Mauvais-Jarvis P, Sitruk-Ware R, Kutenn F (1982) Luteal phase insufficiency and development of breast cancer. Breast Cancer Res Treat 2:139–150

    Article  PubMed  CAS  Google Scholar 

  27. Mauvais-Jarvis P, Sitruk-Ware R, Kutenn F (1983) Luteal phase defect and benign breast disease relationship to breast cancer genesis. J Steroid Biochem 19:13

    Article  Google Scholar 

  28. Mauvais-Jarvis P, Sitruk-Ware R, Kutenn F, Stekers N (1979) Luteal phase insufficiency: A common pathophysiologic factor in the development of benign and malignant breast diseases. Comment Res Breast Dis 1:25–29

    Google Scholar 

  29. Moore JW, Clark GMG, Bulbrook RD, Hayward JL, Murai JT, Hammond GL, Siiteri PK (1982) Serum concentration of total and non-protein-bound estradiol in patients with breast cancer and in normal controls. Int J Cancer 29:17–21

    Article  PubMed  CAS  Google Scholar 

  30. Moore JW, Clark GMG, Hoare SA, Millis RR, Hayward JL, Quinlan MA, Wang DY, Bulbrook RD (1986) Binding of estradiol to blood proteins and etiology of breast cancer. Int J Cancer 38:625–630

    Article  PubMed  CAS  Google Scholar 

  31. Moore JW, Clark GMG, Takatani O, Wakabayashi Y, Hayward JL, Bulbrook RD (1983) Distribution of 17-β-estradiol in the serum of normal British and Japanese women. J Natl Cancer Inst 71:749–754

    PubMed  CAS  Google Scholar 

  32. Olsson H, Ahn P, Kristofferson U, Landing-Olsson M (1984) Hypophysial tumor and gynecomastia preceding bilateral breast cancer development in a man. Cancer 53:1974–1977

    Article  PubMed  CAS  Google Scholar 

  33. Olsson H, Landing-Olsson M, Gullberg B (1983) Retrospective assessment of menstrual cycle length in patients with breast cancer in patients with benign breast disease and in women without breast disease. J Natl Cancer Inst 70:17–20

    PubMed  CAS  Google Scholar 

  34. Peters F, Geisthövel F, Breckwoldt M (1987) Treatment of benign breast disease by dopamine agonists. In: Genazzani AR, Volpe A, Facchetti F (eds) Gynecological Endocrinology. Parthenon, Lancaster, pp 275–283

    Google Scholar 

  35. Rannevik G (1987) Endocrinological aspects of benign breast disease. In: Wood C (ed) Benign breast disease: Is it worth treating? Raven Press, Oxford, pp 17–25 (Round table series Royal Society of Medicine Series No. 6)

    Google Scholar 

  36. Reed MJ, Cheng RW, Noel CT, Dudley HAF, James VHT (1983) Plasma levels of estron, estronesulfate and estradiol and the percentage of unbound estradiol in postmenopausal women with and without breast disease. Cancer Res 43:3940–3943

    PubMed  CAS  Google Scholar 

  37. Schindler AE, Schindler E-M (1986) Ernährung und Karzinomentstehung. In: Schindler AE (Hrsg) Prävention in Gynäkologie und Geburtshilfe. Terramed, Überlingen, S 93–100

    Google Scholar 

  38. Schindler AE, Schindler E-M (1989) Gynäkologie und Geburtshilfe in der Praxis. Hippokrates, Stuttgart

    Google Scholar 

  39. Secreto G, Recchione C, Miralgia M, Grinolso E, Cavalleri A (1984) High testosterone and low progesterone circulating levels in premenopausal patients with hyperplasia and cancer of the breast. Cancer Res 44:841–844

    PubMed  CAS  Google Scholar 

  40. Sherman BM, Korenman SG (1974) Inadequate corpus luteum function: A pathophysiological interpretation of human breast cancer epidemiology. Cancer 33:1306–1309

    Article  PubMed  CAS  Google Scholar 

  41. Siiteri PK, Hammond GL, Nisker JA (1981) Increased availability of serum estrogens in breast cancer, a new hypothesis. In: Pike MC, Siiteri PK, Walsh CW (eds) Hormones and Cancer. (Banbury Report No. 8, Cold Spring Harbour Laboratories) pp 87–101

    Google Scholar 

  42. Sitruk-Ware R, Clair F, Sterkers N, Ulmann A, Mauvais-Jarvis P (1987) Prolactin secretion in benign breast diseases. Gynecol Endocrinol 1:195–200

    Article  PubMed  CAS  Google Scholar 

  43. Thomas BS (1983) Thyroid function and breast disease. In: Bulbrook RD, Taylor DJ (eds) Commentaries on Research in breast disease, vol 3. Liss, New York, pp 34–60

    Google Scholar 

  44. Trichopoulos D, Hsieh Ch, MacMahon B, Lin T, Lowe CR, Mirra AP, Ravnihar B, Sallar EJ, Valakras VG, Yuasa S (1983) Age at any birth and breast cancer risk. Int J Cancer 31:701–704

    Article  PubMed  CAS  Google Scholar 

  45. Trichopoulos D, MacMahon B, Cole P (1972) Menopause and breast cancer risk. J Natl Cancer Inst 48:605–613

    PubMed  CAS  Google Scholar 

  46. Vihko R, Apter D (1984) Endocrine characteristics of adolescent menstrual cycles: Impact of early menarche. J Steroid Biochem 20:231–236

    Article  PubMed  CAS  Google Scholar 

  47. Vorherr H (1986) Fibrocystic breast disease: Pathophysiology, pathomorphology, clinical picture and management. Am J Obstet Gynecol 154:161–179

    PubMed  CAS  Google Scholar 

  48. Walsh PV, McDicken IW, Bulbrook RD, Moore JW, Taylor WH, George WD (1984) Serum estradiol and prolactin concentrations during the luteal phase in women with benign breast disease. Eur J Cancer Clin Oncol 20:1345–1351

    Article  PubMed  CAS  Google Scholar 

  49. Wang DY, Fentinam IS (1985) Epidemiology and endocrinology of benign breast disease. Breast Cancer Res Treat 6:5–36

    Article  PubMed  CAS  Google Scholar 

  50. Wingrave S (1982) Progestogen effects and their relationship to lipoprotein changes. In: A report on the oral contraception study of the Royal College of General Practitioners. Obstet Gynecol Scand [Suppl] 10:33–36

    Google Scholar 

Download references

Authors
  1. A. E. Schindler
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Kreiskrankenhaus Böblingen, Bunsenstr. 120, 7030, Böblingen, Germany

    A. S. Wolf

  2. Frauenklinik der Westfälischen Wilhelms-Universität, Albert-Schweitzer-Straße 33, 4400, Münster, Germany

    H. P. G. Schneider

Rights and permissions

Reprints and permissions

Copyright information

© 1990 Springer-Verlag, Berlin Heidelberg New York

About this paper

Cite this paper

Schindler, A.E. (1990). Die Bedeutung der Östrogene für gutartige und bösartige Brusterkrankungen. In: Wolf, A.S., Schneider, H.P.G. (eds) Östrogene in Diagnostik und Therapie. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-75101-1_4

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-75101-1_4

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-51745-0

  • Online ISBN: 978-3-642-75101-1

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation